Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Bryan Baugh"'
Autor:
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in European Locations (CAR
Externí odkaz:
https://doaj.org/article/cf663c19fbc04c13b44fe74a60666e97
Autor:
Luis Hernandez-Pastor, Jeroen Geurtsen, Bryan Baugh, Antoine C. El Khoury, Nnanya Kalu, Marjolaine Gauthier-Loiselle, Rebecca Bungay, Martin Cloutier, Michal Sarnecki, Elie Saade
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Invasive extraintestinal pathogenic Escherichia coli disease (IED) can lead to severe outcomes, particularly among older adults. However, the clinical burden of IED in the U.S. has not been well characterized. Methods IED encounte
Externí odkaz:
https://doaj.org/article/5a6d3d9236844c2a91cf55a31f39f532
Autor:
Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups
Publikováno v:
HIV Research & Clinical Practice, Vol 21, Iss 6, Pp 151-167 (2021)
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Obje
Externí odkaz:
https://doaj.org/article/0075f5926758485aa79ac9cb573f7b85
Autor:
Keith Dunn, Bryan Baugh, Nika Bejou, Donghan Luo, Jennifer Campbell, Sareh Seyedkazemi, David Anderson
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 21 (2022)
Gastrointestinal intolerance has been associated with ritonavir-boosted protease inhibitors. This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through
Externí odkaz:
https://doaj.org/article/795180296fca4a059a4dd38f80a83900
Autor:
Parul Patel, Susan L. Ford, Mark Baker, Claudia Meyer, Louise Garside, Ronald D'Amico, Rodica Van Solingen‐Ristea, Herta Crauwels, Joseph W. Polli, Ciara Seal, Itziar Yagüe Muñoz, Shanker Thiagarajah, Eileen Birmingham, William R. Spreen, Bryan Baugh, Jean van Wyk, Vani Vannappagari
Publikováno v:
HIV Medicine. 24:568-579
Limited data exist on pregnant women living with HIV exposed to cabotegravir + rilpivirine (CAB + RPV). Outcomes in pregnant participants exposed to CAB + RPV, and pharmacokinetic washout data in those exposed to CAB + RPV long-acting (LA) with live
Autor:
Ronald D'Amico, Santiago Cenoz Gomis, Riya Moodley, Rodica Van Solingen‐Ristea, Bryan Baugh, Erika Van Landuyt, Veerle Van Eygen, Sherene Min, Amy Cutrell, Caroline Foster, Daniella Chilton, Sabine D. Allard, Annemiek Ruiter
Publikováno v:
HIV Medicine. 24:202-211
OBJECTIVES: Physicians could request compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for people living with HIV-1 under a single-patient request programme supported by ViiV Healthcare and Janssen. Outcomes are reported. METH
Autor:
Elie Saade, Jeroen Geurtsen, Bryan Baugh, Antoine El Khoury, Nnanya Kalu, Marjolaine Gauthier-Loiselle, Rebecca Bungay, Martin Cloutier, Luis Hernandez Pastor
Publikováno v:
Open Forum Infectious Diseases. 9
Background The risk of invasive extraintestinal pathogenic Escherichia coli disease (IED) increases with age and can lead to severe outcomes, including sepsis and death. Aim To describe the clinical outcomes of IED in older adults in the United State
Autor:
Parul Patel, Emilie Elliot, Ronald D’Amico, Louise Garside, Conor Smith, Jeremy Roberts, Joseph W Polli, Moti Ramgopal, Princy N Kumar, Olayemi Osiyemi, Bryan Baugh, Jean A van Wyk
Publikováno v:
Open Forum Infectious Diseases. 9
Background Long-acting cabotegravir + rilpivirine (CAB + RPV LA) administered monthly or every 2 months is the first and only complete LA regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. This post hoc an
Autor:
Babafemi O Taiwo, Darrell Tan, Parul Patel, Paula Teichner, Joseph Polli, Louise Garside, Ronald D’Amico, Christine L Talarico, Rodica Van Solingen-Ristea, Bryan Baugh, William Spreen, Michael Aboud, Matthew Bosse
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB) plus rilpivirine (RPV) is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. CAB+RPV LA dosed every 4 weeks (Q4W) or every 8 weeks (Q8W) de
Autor:
Erika Van Landuyt, Erkki Lathouwers, Christoph D. Spinner, Kimberley Brown, Aimee M. Wilkin, Gregory D Huhn, John Jezorwski, Amber, Mohsine El Ghazi, Emerald study groups, Bryan Baugh, Cristina Mussini
Publikováno v:
HIV researchclinical practice. 21(6)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). To describe a W